Discovery Labs Surfaxin update
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Discovery Labs is pushing back its launch plans for Surfaxin (lucinactant) to Q2 2006 due to additional information requested by FDA, the firm says Aug. 19. The company plans to respond within 60 days to a dozen questions from FDA regarding Surfaxin. Among the issues is a question regarding the stability test used by a supplier of one of Surfaxin's active ingredients. Discovery responded to a February "approvable" letter in July, but the response was not deemed complete. FDA "will allow us to amend [the response] with our response to these 12 items," CEO Robert Capetola says. Discovery is seeking an indication for use of Surfaxin in prevention of respiratory distress syndrome in premature infants...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.